Medtronic recently launched the Talent Thoracic Stent Graft on the Xcelerant Delivery System in the US.
Approved by the FDA, the Talent expands the applicability of TEVAR to more patients with thoracic aortic aneurysms: a wide range of sizes so more patients can be treated; improved trackability and controlled deployment for easier and more accurate stent graft placement; and high radial force as shown in competitive bench testing.
Dr Ronald Fairman, Hospital of the University of Pennsylvania, Philadelphia, served as the principal investigator of the clinical study that supported FDA approval of the Talent Thoracic Stent Graft. “Given the wide diameter treatment range, 25% of implanted subjects in the VALOR trial could not have been treated with current commercially available devices,” he said.
